Dechert (Paris)

Mélanie Thill-Tayara

Dechert (Paris)
Partner

Mélanie Thill-Tayara is a partner in Dechert’s Paris office and co-lead of the firm’s Life Sciences practice. Mélanie focuses her practice on antitrust and competition law, and she regularly represents leading companies in cartel and abuse of dominant position cases before EU and French authorities and courts. In addition, Mélanie assists leading companies in merger notifications before the French and European regulators and coordinates multi-jurisdictional filings. She regularly advises clients involved in inspections conducted by the authorities and the subsequent challenges. Prior to joining Dechert in February 2016, she served as a partner for more than 20 years with two other international law firms. Before that, she was an officer at the European Commission, Directorate-General for Competition, where she participated in numerous dawn raid operations and contributed to several decisions. Named Top Woman in Antitrust (GCR Women in Antitrust), Mélanie Thill-Tayara is ranked as one of the top competition and antitrust lawyers in France by Chambers Europe, Legal 500, GCR100, Who’s Who Legal : France and Best Lawyers France 2022.

Distinctions

Auteurs associés

Dechert (New York)
Dechert (Paris)
Dechert (Paris)
Dechert (Moscow)
Dechert (Philadelphia)

39054 | Évènements

Vidéos

Mélanie Thill-Tayara (Dechert)
Mélanie Thill-Tayara 30 novembre 2018 Paris
Mélanie Thill-Tayara (Dechert)
Mélanie Thill-Tayara 30 novembre 2018 Paris
Mélanie Thill-Tayara - Global Merger Control Conference - 2 December 2016
Mélanie Thill-Tayara 2 décembre 2016 Paris

Articles

8153 Bulletin

Mélanie Thill-Tayara, Marion Provost The French Supreme Court rejects an appeal by a pharmaceutical company which alleged that a €21M fine imposed by the competition authority was erroneous (Janssen-Cilag)

43

On 1 June 2022, the French Supreme Court (the “Supreme Court”) entirely dismissed the appeal of Janssen-Cilag (“Janssen”) and its parent company Johnson & Johnson against a judgment of the Paris Court of Appeal (the “Court of Appeal”) of 11 July 2019 in the Durogesic® case. However, this ruling (...)

Mélanie Thill-Tayara, Marion Provost, Sophie Mitouard Dominance in the pharmaceutical sector : an overview of EU and national case law

1069

In a communication of November 2020, the European Commission presented its ‘new Pharmaceutical Strategy for Europe’, the main objective of which is to achieve a strong, fair, competitive, and green pharmaceutical industry, centered on patients’ needs. The Commission’s ambition is to remove existing barriers that prevent patients’ access to innovative and affordable medicines, while facilitating the digital transformation of the industry. In this context, the enforcement of competition rules certainly remains an important instrument for the Commission to achieve its goals and we expect the sector to remain a key priority throughout the European Union. Just in the past year, several important decisions have been adopted and multiple investigations opened, both in antitrust and merger control.

Christophe De Vienne, Mélanie Thill-Tayara, Laurence Bary The EU Court of Justice declares that financial investors are liable for anti-competitive conduct of portfolio companies (Goldman Sachs)

175

The European Court of Justice has confirmed that financial investors can incur parental liability for the anticompetitive practices of portfolio companies, even after an IPO that left the investor holding only a minority stake in the company, provided that they still have sufficient (...)

Mélanie Thill-Tayara, Laurence Bary, Marion Provost The EU Court of Justice confirms that financial investors can incur parental liability for the anticompetitive practices of their portfolio companies (Goldman Sachs)

22

This article has been nominated for the 2021 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. The European Court of Justice has confirmed that financial investors can incur parental liability for the anticompetitive practices of portfolio companies, even (...)

Mélanie Thill-Tayara, Laure Arnaud, Marion Provost The EU General Court partially annuls the Commission’s decision authorizing unannounced dawn raids to be carried out at the headquarters of two French food retail chains (Casino, Guichard-Perrachon / Achats Marchandises Casino) (Intermarché Casino Achats) (Les Mousquetaires / ITM Entreprises)

208

In three recent judgments issued on 5 October 2020, the General Court of the European Union ("GCEU") partially annulled the European Commission’s ("Commission") decisions of February 2017 which had authorized onsite unannounced inspections ("dawn raid”) to be carried out at the headquarters of (...)

Laurence Bary, Alec J. Burnside, Mélanie Thill-Tayara, Clemens York von Wartenburg The European Competition Network issues a general joint statement on the application of competition rules during the COVID-19 outbreak

496

Key Takeaways Following several individual initiatives by member state competition authorities to temporarily relax competition rules in specific sectors, the European Competition Network (which includes the European Commission and all member state competition authorities) has issued a more (...)

Mélanie Thill-Tayara, Marion Provost The Paris Court of Appeal clarifies the relevant test for characterizing an excessive price in the market of waste disposal for hospitals and clinics in Corsica (Sanicorse)

152

On 14 November 2019, the Paris Court of Appeal (the “Court”) quashed a decision of the French Competition Authority (“FCA”) of 20 September 2018 in which the latter had imposed € 199 000 fine on Sanicorse for having abused its dominant position on the market for infectious clinical waste (“ICW”) (...)

Mélanie Thill-Tayara, Marion Provost, Sophie Mitouard The Paris Court of Appeal upholds the decision of the Competition Authority to fine a pharma company for abuse of dominance (Jansson-Cilag / Johnson & Johnson)

124

More particularly, the Court affirmed the FCA’s conclusion that Janssen infringed competition law by, on the one hand, disparaging competing fentanyl specialties towards health professionals, emphasizing the risks associated with a switch from Durogesic© to a generic version and, on the other (...)

Marion Provost, Mélanie Thill-Tayara, Simon Hetsch, Sophie Pelé The EU General Court annuls a decision of the Commission for wrongly qualifying agreements as "pay for delay" and improperly qualifying an abuse of dominance, thus reducing the fine imposed on a pharmaceutical company (Servier)

532

The General Court annuls in part the European Commission’s decision finding the existence of restrictive agreements and an abuse of a dominant position on the market for perindopril, a medicine used to treat hypertension and heart failure* On 12 December 2018, the General Court (“Court”) (...)

Alec J. Burnside, Clemens York von Wartenburg, Laurence Bary, Mélanie Thill-Tayara The EU General Court finds financial investors liable for anticompetitive conduct of portfolio companies over which they hold decisive influence (Goldman Sachs)

163

The General Court of the European Union recently held, in Goldman Sachs v. Commission, that purely financial investors such as investment funds may be held jointly and severally liable for competition law violations implemented by their portfolio companies when they can exercise “decisive (...)

Alec J. Burnside, Anne MacGregor, Mélanie Thill-Tayara, Romain Maulin The EU Court of Justice orders new assessment in a case of abuse of dominance by a semi-conductor company granting loyalty rebates (Intel)

250

EU Court Orders New Assessment of Intel’s Rebates The Court of Justice of the European Union (CJEU) has quashed a ruling by the EU’s General Court which had upheld the European Commission’s (EC) 2009 finding of abuse of dominance by Intel Corporation Inc. Intel was fined €1.06 billion, a record at (...)

9621 Revue

Franck Audran, Martine Behar-Touchais, Frédéric Buy, Walid Chaiehloudj, Antoine Choffel, Sophie Harnay, Stéphane de La Rosa, Sophie Pelé, Marion Provost, Mélanie Thill-Tayara Emmanuel Macron, Ministre et Président : un bilan concurrentiel plutôt positif

3679

Quel bilan concurrentiel pour Emmanuel Macron, Ministre de l’Economie puis Président de la République ? Il est remarquable qu’Emmanuel Macron a eu une volonté réformatrice très forte en droit de la concurrence, et de la distribution, en ouvrant les marchés (professions réglementées, transport par car, (...)

Laurence Idot, Mélanie Thill-Tayara, Laurence Bary Autorités de concurrence : Quel contrôle juridictionnel ? (Demain la concurrence - Paris, 14 juin 2019)

690

Les présentes contributions ont été rassemblées à la suite de la 10ème édition de la conférence annuelle “Demain la concurrence” organisée par la Revue Concurrences le 14 juin 2019, au Ministère de l’Économie et des Finances à Paris. Les débats s’organisaient autour de quatre thèmes. Les membres de la (...)

Mélanie Thill-Tayara, Stanislas Martin Stanislas Martin (Autorité de la concurrence) : Quel équilibre entre efficacité des procédures de concurrence et droits de la défense ?

1228

Interview réalisée par Mélanie Thill-Tayara, Associée, Dechert, Paris. Diplômé de l’Institut d’études politiques de Paris et de l’ENA, vous avez occupé plusieurs postes au sein de la DGCCRF, travaillé pour la Représentation permanente de la France auprès de l’Union européenne et, moins classique, avez (...)

Andreas Mundt, Bruno Lasserre, Mélanie Thill-Tayara, Peter Freeman, Wouter Wils Règlement 1/2003 et Réseau européen de concurrence 10 ans après : Faut-il étendre la coopération au contrôle des concentrations et à l’advocacy ? (New Frontiers of Antitrust, Paris, 21 February 2014)

861

La troisième table-ronde de la conférence “Demain la concurrence” du 21 février 2014 à Paris, était dédiée au “Règlement 1/2003 et Réseau européen de concurrence 10 ans après : Faut-il étendre la cooperation au contrôle des concentrations et à l’advocacy ?”. Les objectifs pour les auteurs de cette table ronde (...)

Livres

Envoyer un message